Among persons living with HIV in the United States, an estimated 15 to 30% have HCV coinfection. For persons living with HIV who have HCV coinfection, liver-related morbidity and mortality is a prominent non-AIDS-related complication—up to 80 to 90% of liver-related deaths in persons living with HIV are attributable to HCV infection-and proper treatment remains a priority. This webinar will discuss HIV/HCV co-infection, particularly among people who inject drugs, and evidence-based prevention and treatment strategies.

CEU Available

Learning Objectives:

• Discuss the epidemiology of HIV and HCV infections in populations of people who use drugs, particularly those who inject drugs.
• Outline established and emerging strategies to prevent infection in these individuals.
• Evaluate the approach to treatment of HIV and HCV in these individuals.

Faculty:
Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. He is founding Director of the Johns Hopkins Office of Clinical Trials and Senior Associate Dean for Clinical Trials and Research in the Capital Region (CAPRES). He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine. Dr. Sulkowski has been the principal investigator for more than 120 clinical trials related to the management of viral hepatitis B and C in persons with and without HIV co-infection.

Register now at https://us06web.zoom.us/webinar/register/WN_g1HHR6VaQjGm8K9s1X6LLg